In Vitro Characterization and In Vivo Effectiveness of Ebola Virus Specific Equine Polyclonal F(ab’)2

Publications scientifiques 02.19 In Vitro Characterization and In Vivo Effectiveness of Ebola Virus Specific Equine Polyclonal F(ab')2 The Journal of Infectious Diseases Trina Racine 1 2 3 , Mélanie Denizot 4 , Delphine Pannetier 5 , Ludovic Nguyen 4 , Anaïs Pasquier 4 , Hervé Raoul 5 , Jean-François Saluzzo 4 , Gary Kobinger 2 6 3 7 , Francisco Veas 8 , Cécile H Herbreteau 4 Abstract There is no vaccine or approved therapy against lethal Ebola virus (EBOV). We investigated a proven technology platform to produce polyclonal IgG fragments, F(ab’)2, against EBOV. Horses immunized with nanoparticles harboring surface glycoprotein trimers of EBOV-Zaire/Makona produced anti-Ebola IgG polyclonal antibodies with high neutralization activity. Highly purified equine anti-Ebola F(ab’)2 showed strong cross-neutralization of 2 Zaire EBOV strains (Gabon 2001 and Makona) and in vivo 3 or 5 daily F(ab’)2 intraperitoneal injections provided 100% protection to BALB/c mice against lethal EBOV challenge. Rapid preparation of purified equine anti-Ebola F(ab’)2 offers a potentially efficient therapeutic approach against EBOV disease in humans. Keywords: Ebola; F(ab′)2 fragments; equine; immunoglobulins. © The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: [email protected]. The Journal of Infectious Diseases , Volume 220, Issue 1, 1 July 2019, Pages 41–45 Access full publication Affiliations 1 Special Pathogens Program, National Microbiology Laboratory, Winnipeg, Canada. 2 Department of Medical Microbiology, Winnipeg, Canada. 3 Centre de Recherche en Infectiologie, Centre Hospitalier Universitaire de Québec, Université Laval, Canada. 4 Fab’entech, Lyon, France. 5 INSERM, Jean Mérieux BSL-4 Laboratory, Lyon, France. 6 Department of Immunology, University of Manitoba, Winnipeg, Canada. 7 Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia. 8 Institut de Recherche pour le Développement, UMR-Ministère de la Défense, Faculté de Pharmacie, Université de Montpellier, France. Plus d'actualités 01.2023 Potent Neutralizing Activity of Polyclonal Equine Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern Publications scientifiques 12.2017 Past, present and future therapeutic and prophylactic strategies against arenaviruses responsible of human hemorrhagic fever Publications scientifiques 07.2016 Efficacy of a specific polyclonal equine F(ab’)2 against avian influenza (H5N1) in ferrets: synergy with oseltamivir Publications scientifiques

The release as fetched from its publisher. fabentech.com ↗